Neumora Therapeutics (NMRA) Competitors $0.85 -0.05 (-5.32%) As of 01:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. ZVRA, AMLX, PRTC, SEPN, ORKA, TRML, MBX, MGTX, SIGA, and ZYBTShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Zevra Therapeutics (ZVRA), Amylyx Pharmaceuticals (AMLX), PureTech Health (PRTC), Septerna (SEPN), Oruka Therapeutics (ORKA), Tourmaline Bio (TRML), MBX Biosciences (MBX), MeiraGTx (MGTX), SIGA Technologies (SIGA), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Its Competitors Zevra Therapeutics Amylyx Pharmaceuticals PureTech Health Septerna Oruka Therapeutics Tourmaline Bio MBX Biosciences MeiraGTx SIGA Technologies Zhengye Biotechnology Neumora Therapeutics (NASDAQ:NMRA) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership. Does the MarketBeat Community believe in NMRA or ZVRA? Zevra Therapeutics received 9 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. Likewise, 95.12% of users gave Zevra Therapeutics an outperform vote while only 75.00% of users gave Neumora Therapeutics an outperform vote. CompanyUnderperformOutperformNeumora TherapeuticsOutperform Votes3075.00% Underperform Votes1025.00% Zevra TherapeuticsOutperform Votes3995.12% Underperform Votes24.88% Is NMRA or ZVRA more profitable? Neumora Therapeutics has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -342.63%. Neumora Therapeutics' return on equity of -73.63% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -73.63% -68.97% Zevra Therapeutics -342.63%-159.54%-51.50% Which has more volatility & risk, NMRA or ZVRA? Neumora Therapeutics has a beta of 2.73, suggesting that its stock price is 173% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500. Do institutionals and insiders hold more shares of NMRA or ZVRA? 47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 26.8% of Neumora Therapeutics shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor NMRA or ZVRA? In the previous week, Zevra Therapeutics had 5 more articles in the media than Neumora Therapeutics. MarketBeat recorded 7 mentions for Zevra Therapeutics and 2 mentions for Neumora Therapeutics. Zevra Therapeutics' average media sentiment score of 1.29 beat Neumora Therapeutics' score of 0.93 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, NMRA or ZVRA? Zevra Therapeutics has higher revenue and earnings than Neumora Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$235.93M-$1.61-0.54Zevra Therapeutics$40.59M12.53-$46.05M-$1.90-4.89 Do analysts recommend NMRA or ZVRA? Neumora Therapeutics currently has a consensus target price of $9.29, suggesting a potential upside of 966.10%. Zevra Therapeutics has a consensus target price of $22.29, suggesting a potential upside of 139.63%. Given Neumora Therapeutics' higher probable upside, equities analysts clearly believe Neumora Therapeutics is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 SummaryZevra Therapeutics beats Neumora Therapeutics on 10 of the 18 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$140.88M$3.10B$5.62B$8.58BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-0.4732.7127.1919.81Price / SalesN/A459.10408.23154.60Price / CashN/A168.6838.3234.64Price / Book0.283.386.994.65Net Income-$235.93M-$72.35M$3.23B$248.05M7 Day Performance-14.61%1.10%-0.18%-0.26%1 Month Performance28.20%18.28%8.61%4.37%1 Year Performance-91.25%-17.91%32.26%13.65% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics1.9757 of 5 stars$0.85-5.3%$9.29+992.4%-91.0%$137.49MN/A-0.45108Gap DownZVRAZevra Therapeutics2.872 of 5 stars$8.66+1.3%$22.29+157.3%+88.2%$473.53M$40.59M-4.4020Positive NewsAnalyst RevisionAMLXAmylyx Pharmaceuticals4.1693 of 5 stars$5.10-1.0%$9.83+92.8%+222.8%$454.62M-$1.27M-1.34200Gap DownPRTCPureTech Health2.2357 of 5 stars$18.47+0.2%$45.00+143.7%-34.2%$443.51M$4.32M0.00100Positive NewsSEPNSepterna2.1659 of 5 stars$9.93+7.4%$27.00+171.9%N/A$442.46M$977K0.00N/APositive NewsAnalyst RevisionGap DownORKAOruka Therapeutics3.0771 of 5 stars$11.77+7.4%$40.38+243.0%N/A$440.68MN/A-1.88N/APositive NewsGap DownTRMLTourmaline Bio2.857 of 5 stars$17.11+2.6%$49.33+188.3%+22.9%$439.47MN/A-6.0744Positive NewsAnalyst RevisionGap DownHigh Trading VolumeMBXMBX Biosciences2.0354 of 5 stars$13.14+5.8%$37.50+185.4%N/A$439.19MN/A0.0036Positive NewsMGTXMeiraGTx4.6304 of 5 stars$5.46+6.6%$24.00+339.6%+40.5%$438.79M$34.51M-4.51300SIGASIGA Technologies2.4619 of 5 stars$6.08+1.7%N/A-18.3%$434.36M$120.33M5.0740News CoverageOptions VolumeZYBTZhengye BiotechnologyN/A$9.16+1.6%N/AN/A$432.04M$189.75M0.00278Gap DownHigh Trading Volume Related Companies and Tools Related Companies Zevra Therapeutics Competitors Amylyx Pharmaceuticals Competitors PureTech Health Competitors Septerna Competitors Oruka Therapeutics Competitors Tourmaline Bio Competitors MBX Biosciences Competitors MeiraGTx Competitors SIGA Technologies Competitors Zhengye Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
